USANA Health Sciences (NYSE:USNA) Raised to “Strong-Buy” at Zacks Research

USANA Health Sciences (NYSE:USNA) was upgraded by investment analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Monday,Zacks.com reports.

Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised USANA Health Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a research report on Friday, March 27th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, USANA Health Sciences has an average rating of “Moderate Buy”.

USANA Health Sciences Stock Up 1.8%

USNA opened at $18.50 on Monday. The firm has a market capitalization of $341.51 million, a P/E ratio of 33.64, a price-to-earnings-growth ratio of 0.76 and a beta of 0.71. The stock’s 50 day moving average price is $18.91 and its two-hundred day moving average price is $20.23. USANA Health Sciences has a 12-month low of $16.60 and a 12-month high of $38.32.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.19. USANA Health Sciences had a return on equity of 6.75% and a net margin of 1.16%.The company had revenue of $226.20 million during the quarter, compared to analysts’ expectations of $225.96 million. As a group, analysts anticipate that USANA Health Sciences will post 2.45 earnings per share for the current year.

Insider Activity

In other news, insider Joshua Foukas sold 4,461 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $21.34, for a total transaction of $95,197.74. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 0.63% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in USNA. State of Alaska Department of Revenue boosted its stake in shares of USANA Health Sciences by 8.5% in the 4th quarter. State of Alaska Department of Revenue now owns 6,666 shares of the company’s stock valued at $130,000 after purchasing an additional 525 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of USANA Health Sciences by 4.6% in the 4th quarter. Russell Investments Group Ltd. now owns 12,431 shares of the company’s stock valued at $244,000 after purchasing an additional 542 shares in the last quarter. Quantbot Technologies LP boosted its stake in shares of USANA Health Sciences by 19.5% in the 2nd quarter. Quantbot Technologies LP now owns 3,957 shares of the company’s stock valued at $121,000 after purchasing an additional 646 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of USANA Health Sciences by 13.5% in the 3rd quarter. Intech Investment Management LLC now owns 7,722 shares of the company’s stock valued at $213,000 after purchasing an additional 918 shares in the last quarter. Finally, National Bank of Canada FI boosted its stake in shares of USANA Health Sciences by 166.6% in the 3rd quarter. National Bank of Canada FI now owns 1,922 shares of the company’s stock valued at $53,000 after purchasing an additional 1,201 shares in the last quarter. 54.25% of the stock is owned by institutional investors.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah?based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight?management products and skin?care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical?grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.